AGARWALEYE (AGARWALEYE) Fair Value & Analysis
Healthcare · Market cap ₹151B
Fair value as of: Jul 3, 2026
From 25 valuation models · updated today
Price vs Fair Value (12 months)
12‑month range ₹406.55 – ₹545.70 · fair‑value band ₹63.03 – ₹105.05 · the ₹476.60 price screens above the ₹84.04 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
AGARWALEYE (AGARWALEYE) currently trades at ₹476.60, while our model-based Fair Value estimate is ₹84.04 — implying the stock looks roughly 82.4% overvalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, AGARWALEYE generated revenue of ₹20.8B at a net margin of 6.4%. Revenue grew 22.6% year over year. It earns a return on equity of 8.3%. Net debt stands at ₹9.4B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
AGARWALEYE reported revenue of ₹20.8B in FY2026 versus ₹7.0B in FY2022, a compound +31.5%/yr. Reported net income was ₹1.3B in FY2026, compounding +37.1%/yr from FY2022.
Is AGARWALEYE fairly valued? → Check now
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $143.92 | $104.17 | -28% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AGARWALEYE (AGARWALEYE) undervalued?
What is the fair value of AGARWALEYE?
What is the quality score of AGARWALEYE?
What is the revenue of AGARWALEYE (AGARWALEYE)?
What is the net profit margin of AGARWALEYE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.